Total
0
Shares
Bod Australia (ASX:BDA) - CEO, Jo Patterson
CEO, Jo Patterson
Source: InvestorStream
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Bod Australia (BDA) receives $2.24 million in customer receipts for the June quarter which marks a 20 per cent increase on the March quarter
  • This takes the total unaudited customer receipts for FY21 to $6.62 million — an 83 per cent growth on FY20
  • Bod attributes the increases to a rise in sales of its medicinal cannabis products which it sold 4441 of in the June quarter
  • Bod also celebrated its highest-ever month of medicinal cannabis sales in April when it filled 1789 MediCabilis prescriptions.
  • CEO Jo Patterson expects sales growth to continue as it scales up operations and product launches across Australia, the US and the UK
  • Company shares are down 1.49 per cent to trade at 33 cents

Bod Australia (BDA) enjoyed a number of financial and operational highlights during the June 2021 quarter.

The medicinal cannabis and hemp healthcare company saw a 20 per cent increase in customer receipts to $2.24 million on the previous quarter. This takes the total unaudited receipts for the entire 2021 financial year to $6.62 million — marking an 83 per cent growth from FY20.

The increased customer receipts can be attributed to a growth in product sales which were up 17 per cent on the prior quarter.

Specifically, Bod sold 4441 medicinal cannabis product units which takes the total number for FY21 to 12,187. This is a 212 per cent increase from the 3907 sold in FY20.

Bod also celebrated its highest-ever month of medicinal cannabis sales in April when it filled 1789 MediCabilis prescriptions.

Continuing the growth trend, Bod retained 55 per cent of the total market share for full plant high CBD products which allowed it to capture 46 per cent of that market over FY21.

CEO Jo Patterson was pleased with the company’s continued growth over the quarter.

“The increases in receipts from customers, as well as overall revenue are very pleasing and this upward trajectory will continue over the coming months and fiscal year ahead. We continue to receive a very high demand for our medicinal cannabis product suite,” Ms Patterson said.

“We have added a number of products under our established brand recently and expect that scale up of operations in both Australia and the UK will lead to a further increase in sales.”

Positively for Bod, it received its first purchase order from the US. In April, Health and Happiness Group made a $312,000 order for Bod’s CBD products.

As part of this deal, the companies are launching the premium CBD brand “CBII” directly to consumers through eCommerce platforms. The company also plans to launch new products under CBII across the US and other established markets.

Additionally, Bod launched a new cannabigerol (CBG) product which will be sold under the MediCabilis brand in the UK. The company expects this will expand its presence in the region and offer more opportunities.

At the end of the quarter, Bod had $8.07 million in cash which it said offers financial flexibility to continue growth prospects.

Company shares were down 1.49 per cent to trade at 33 cents at 2:39 pm AEST.

BDA by the numbers
More From The Market Herald
APM (ASX:APM) - CEO, Michael Anghie

" APM Human Services (ASX:APM) expands, acquiring Lifecare

APM Human Services International (APM) has acquired physiotherapy and home care group Lifecare for $68 million.
Resonance Health (ASX:RHT)

" Resonance Health (ASX:RHT) submits LiverSmart to FDA

Resonance Health (RHT) has submitted its LiverSmart device to the Food and Drug Administration (FDA) for US regulatory clearance.
Dotz Nano (ASX:DTZ) - CEO, Gideon Shmuel

" Dotz Nano (ASX:DTZ) signs Malaysian distribution deal for COVID-19 tests

Dotz Nano (DTZ) has entered into a distribution agreement with ScienceVision to promote, sell and distribute its COVID-19 virus detection technology in Malaysia.
Kazia Therapeutics (ASX:KZA) - CEO, Dr James Garner

" Kazia Therapeutics (ASX:KZA) releases “positive” second-phase study results for brain cancer treatment

Kazia Therapeutics (KZA) has opened the trading day green after reporting positive final results from a second-phase clinical study of its paxalisib drug